Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 65 Neoplasms 31 Small Cell Lung Carcinoma 26 Carcinoma, Hepatocellular 24 Melanoma 23 Colorectal Neoplasms 23 Triple Negative Breast Neoplasms 20 Carcinoma, Renal Cell 20 Carcinoma, Transitional Cell 19 Breast Neoplasms 18 Neoplasm Metastasis 14 Urinary Bladder Neoplasms 13 Stomach Neoplasms 12 Uterine Cervical Neoplasms 11 Solid Tumors 11 Squamous Cell Carcinoma of Head and Neck 10 Ovarian Neoplasms 8 Lymphoma 7 Lung Neoplasms 7 Lymphoma, Non-Hodgkin 6 Head and Neck Neoplasms 6 Esophageal Neoplasms 6 Pancreatic Neoplasms 5 Liver Neoplasms 5 Carcinoma, Merkel Cell 5 Advanced Solid Tumor 5 Solid Tumor 4 Prostatic Neoplasms 4 Leukemia, Myeloid, Acute 4 Kidney Neoplasms 4

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Anal Cancer Metastatic × atezolizumab × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡